Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

NCT07270432 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2025-12-08

No results posted yet for this study

Summary

To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia

Conditions

  • Prostatic Hyperplasia, Benign

Interventions

DRUG

Product DNN.65.21.005

One capsule every 24 hours

DRUG

Combodart®

One capsule every 24 hours

Sponsors & Collaborators

  • Ache Laboratorios Farmaceuticos S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2027-04-30
Completion
2027-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07270432 on ClinicalTrials.gov